Breaks Categories: News

ThursdayJul 10, 2025 11:37 am

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Raises $4.6 Million Through Warrant Exercise Agreement

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech firm developing targeted therapies for genetic medicine delivery, announced a definitive agreement for the immediate cash exercise of outstanding warrants totaling 6,595,000 shares of common stock at a reduced price of $0.70 per share. The transaction is expected to generate approximately $4.6 million in gross proceeds. In exchange, the company will issue new unregistered warrants with the same share count, exercisable in six months at $0.70 and valid for five and a half years. Ladenburg Thalmann & Co. Inc. is serving as exclusive placement agent. Calidi plans to use the net proceeds…

Continue Reading

ThursdayJul 10, 2025 9:30 am

BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) Completes Historic REVIVE Trial, Sets Stage for Long COVID Breakthrough and Market Expansion 

Fifty 1 Labs (OTC: FITY), through its subsidiary Fifty1 AI Labs, LLC, announced the successful completion of the REVIVE Adaptive Platform Trial (NCT06128967), a groundbreaking Phase III study and the largest Long COVID trial to date. Conducted with global partners and top institutions including Stanford and Duke, the randomized, double-blind trial enrolled over 600 participants and demonstrated a clear treatment benefit using repurposed medicines. Powered by FITY’s proprietary AI platform, the trial sets a new standard in drug repurposing and personalized medicine, while supporting the company’s broader strategy to lead the $320.6 billion functional medicine market, pursue strategic acquisitions, and…

Continue Reading

WednesdayJul 09, 2025 11:31 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Lead Program in Virtual CEO Segment 

  CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on treating primary and metastatic cancers in the brain and central nervous system, announced CEO John Climaco’s participation in a Virtual Investor CEO Connect segment. Climaco provided an overview of the Company’s lead candidate, TPI 287, and shared insights from the Longwood Healthcare Leaders Spring 2025 Meeting in Cambridge, Massachusetts. To view the full press release, visit https://ibn.fm/9Trwm About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.…

Continue Reading

WednesdayJul 09, 2025 9:00 am

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Targets Multiple 2025–2026 Catalysts Across Rare Disease Pipeline

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing therapies for rare diseases with unmet medical needs, issued a shareholder update outlining key clinical and strategic milestones. President and CEO Dr. Christopher J. Schaber highlighted upcoming data readouts for lead candidates, including Phase 3 FLASH 2 results for HyBryte(TM) (synthetic hypericin) in cutaneous T-cell lymphoma expected in 2H 2026, and multiple updates in 3Q and 4Q 2025 across psoriasis (SGX302) and Behçet’s Disease (SGX945). An investigator-initiated study also showed a 75% success rate at 18 weeks. The company projects HyBryte(TM) peak U.S. annual sales of over $90 million and global opportunities…

Continue Reading

TuesdayJul 08, 2025 12:18 pm

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Featured in Editorial Highlighting Breakthrough Genetic Medicine Platform 

Calidi Biotherapeutics (NYSE American: CLDI) announced its feature in a NetworkNewsWire editorial discussing the company’s precision genetic medicine platform, which targets both primary and metastatic cancer tumors using engineered viruses. With global cancer diagnoses expected to reach 35 million annually by 2050, Calidi’s approach represents a potential breakthrough in addressing critical unmet needs. The company’s platform aims to deliver potent genetic therapies directly to cancer sites, offering a novel and potentially disruptive solution in the fight against cancer. To view the full press release, visit: https://ibn.fm/nMiOZ About Calidi Biotherapeutics Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology designed…

Continue Reading

TuesdayJul 08, 2025 9:30 am

BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) Launches Bold AI-Driven Strategy to Reach $50 Million Valuation and Target NASDAQ Uplisting 

Fifty 1 Labs (OTC: FITY), a Nevada-based innovator in AI-driven drug repurposing and functional medicine, unveiled a strategic “Game Plan” aimed at achieving a $50 million valuation and uplisting to the OTCQB by Q1 2026, with long-term plans to join the NASDAQ Capital Market. Backed by a $350,000 insider investment and leadership salary deferrals, FITY is advancing its wholly owned subsidiary, Fifty1 AI Labs LLC, with a $1 million R&D initiative to discover repurposed treatments by May 2026. The company will launch a digital platform by July 31, 2025, pursue biotech acquisitions in the $5–10 million range, and host a…

Continue Reading

WednesdayJul 02, 2025 11:40 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Declares 25% Preferred Stock Dividend Linked to AVERSA Fentanyl Approval 

Nutriband (NASDAQ: NTRB) announced that its Board of Directors has approved a 25% preferred stock dividend, granting one preferred share for every four common shares held as of July 25, 2025, with distribution set for August 5. Each preferred share will convert to one common share upon FDA approval of the Company’s AVERSA Fentanyl product. If not converted, preferred shares will be eligible for annual cash dividends from company profits at the Board’s discretion. CEO Gareth Sheridan said the move reflects the Company’s commitment to shareholder value as it advances toward AVERSA commercialization. To view the full report, visit https://nnw.fm/NdG7s…

Continue Reading

TuesdayJul 01, 2025 9:40 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Added to Four Russell Indexes in 2025 Reconstitution

Nutriband (NASDAQ: NTRB) has been added to the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth Indexes as part of the 2025 Russell indexes reconstitution. CEO Gareth Sheridan called the inclusion a reflection of market recognition and momentum behind the company’s AVERSA pipeline, particularly AVERSA Fentanyl, which has potential peak annual U.S. sales between $80 million and $200 million. Russell indexes, maintained by FTSE Russell, benchmark approximately $10.6 trillion in assets and are widely used by investment managers and institutions. To view the full report, visit https://ibn.fm/wa35e About Nutriband Inc. Nutriband is primarily engaged in the development…

Continue Reading

MondayJun 30, 2025 12:33 pm

BioMedNewsBreaks — HealthLynked Corp. (OTCQB: HLYK) Appoints Andrew Mavliev as Chief Technology and Product Officer

HealthLynked (OTCQB: HLYK), a connected healthcare technology company, has named Andrew Mavliev as its new Chief Technology and Product Officer. Mavliev, a seasoned executive with over 15 years of experience in technology strategy and product development, previously served as founding CTO of Aram Meem LLC’s ToYou superapp. At HealthLynked, he will lead efforts to expand its AI-powered healthcare platform, telehealth services, and integrated medical record systems. CEO Dr. Michael Dent praised Mavliev’s track record of scaling secure, compliant DTC platforms, saying his leadership will support the company’s push for more accessible and personalized care. To view the full press release,…

Continue Reading

MondayJun 30, 2025 9:30 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Advances Regulatory Strategy for CNM-Au8 with FDA Meetings Scheduled for ALS and MS Programs

Clene (NASDAQ: CLNN) announced key regulatory developments following a Type C meeting with the FDA, where it received feedback on its statistical analysis plan (SAP) for evaluating neurofilament light (NfL) biomarker data from its Expanded Access Protocol for ALS. The company has resubmitted a revised SAP and anticipates FDA acceptance this summer, with NfL analyses scheduled for early Q4 2025 to support a potential NDA submission under the accelerated approval pathway. Clene also confirmed two additional FDA meetings in Q3 2025: one to assess long-term ALS survival data for accelerated approval consideration and another End-of-Phase 2 Type B meeting to review…

Continue Reading